Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

The global Personalized Medicine Market is valued at USD 550.2 Billion in 2024 and is projected to reach a value of USD ...

Market OverviewThe global Vaccines Market has evolved significantly in recent years, driven by advancements in biotechnology, ...

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology t ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Aspargo Labs, Inc. ("Aspargo Labs" or the "Company"), a specialty pharmaceutical and MedTech company focused on converting ...

This renewed engagement underscores the strong potential and mutual interest in deepening bilateral economic cooperation ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GSK ...

The Law Offices of Frank R. Cruz reminds investors of the upcoming April 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors ...

In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...

Syngene International appoints Peter Bains as MD & CEO. Syngene International announced that its board approved the ...